About the Immune Tolerance Network

The *Immune Tolerance Network* **(ITN; immunetolerance.org)** is a collaborative network for clinical research focused on the development of therapeutic approaches for asthma and allergy, autoimmune diseases, type 1 diabetes and solid organ transplantation that lead to immune tolerance. These tolerogenic approaches aim to reprogram the immune system so that disease-causing immune responses are stopped while maintaining the immune system's ability to combat pathogen infection. The Network develops, funds and conducts mechanistic, laboratory-based studies in conjunction with clinical trials through collaborations with academic, governmental and industry researchers.

The ITN is funded by a grant from the National Institute of Allergy and Infectious Disease of the National Institutes of Health awarded to the Benaroya Research Institute (Seattle, WA), in partnership with the University of California San Francisco and the Massachusetts General Hospital.

ITN by the Numbers

- **14 years of successful clinical trials** – established in 2000
- **60 total clinical trials** – 13 Allergy; 27 Autoimmunity; 20 Transplant
- **250+ clinical sites** and investigators at leading academic hospitals worldwide
- **3000+ patients** enrolled in ITN clinical trials
- **100+ tolerant patients** off of all immunosuppression to date
- **14 core labs** performing standardized routine and specialized assays
- **500,000 clinical specimens** in the ITN repository

ITN TrialShare (ITNTrialShare.org) has been developed by the ITN as a clinical research portal that provides a comprehensive set of features and tools designed to foster open access to data generated in clinical trials. The ITN has a major commitment towards improved clinical trial transparency and increased access to clinical trial results. We believe in fostering data sharing – encouraging researchers to access participant-level data for ITN trials, over-and-above the data published in the scientific literature. ITN TrialShare allows researchers to re-run and validate statistical analyses and interactively perform their own exploratory analyses within an online system, while enabling the publication of fully interactive figures for manuscript submission and review.

ITN TrialShare provides public access to comprehensive de-identified participant-level data for 21 studies, including specialty assay data such as gene expression, flow cytometry, and sequencing T-cell repertoire files. In addition, analysis datasets and code supporting findings are available from ITN publications including those in the New England Journal of Medicine (NEJM), Journal of Clinical Investigation (JCI) and the Journal of the American Medical Association (JAMA), among others.

ITN TrialShare received the National Academies of Sciences BRDI "Data and Information Challenge" Award in October 2014, recognizing the ITN's leadership in using data for the public good.